Status:
COMPLETED
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms
Lead Sponsor:
United States Department of Defense
Conditions:
Ovarian Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This study will evaluate the expression of arginine vasopressin (AVP) by peptide and mRNA quantitation and also measurement of its V1 receptor mRNA, in the arteries and veins of ovarian malignant (can...
Detailed Description
d. STATUS: Background and Significance/Preliminary Studies Neovascularization is an obligate early event in cancer growth. Consequently, angiogenesis appears to play an important role in disease prog...
Eligibility Criteria
Inclusion
- All patients who have had gynecologic tissue removed for benign (noncancerous) or malignant (cancerous) indications.
Exclusion
- Patients who have a malignancy that is not a primary gynecologic malignancy.
- Age less than 18
- Males
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2009
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00160472
Start Date
March 1 2004
End Date
January 1 2009
Last Update
February 26 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tripler Army Medical Center
Honolulu, Hawaii, United States, 96859